Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Multiple Myeloma 2Glioma 2Triple Negative Breast Neoplasms 1Recurrence 1Neoplasm Metastasis 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Glioblastoma 1Endometrial Neoplasms 1Endometrial Cancer Recurrent 1Diffuse Intrinsic Pontine Glioma 1Colorectal Neoplasms 1Colonic Neoplasms 1

Interventions

pembrolizumab 20Carboplatin 14Cyclophosphamide 12atezolizumab 11Paclitaxel 10Albumin-Bound Paclitaxel 8Capecitabine 7Nivolumab 6130-nm albumin-bound paclitaxel 6spartalizumab 5fludarabine 5Taxes 5Gemcitabine 5talazoparib 4bintrafusp alfa protein, human 4avelumab 4Cisplatin 4sacituzumab govitecan 3olaparib 3entinostat 3Leucovorin 3Ipilimumab 3Immunoglobulin G 3Drug Therapy 3Doxorubicin 3Docetaxel 3Biopsy 32,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 3trilaciclib 2eribulin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Triple Negative Breast Neoplasms × TIC10 compound × Clear all
NCT03733119 2022-03-10

ONC201 With a Methionine-Restricted Diet in Patients With Metastatic Triple Negative Breast Cancer

University of Wisconsin, Madison

Phase 2 Terminated
4 enrolled 10 charts
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡